Heparin versus placebo for acute coronary syndromes

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Magee, Kirk D ^a   Campbell, S G ^b   Moher, D ^b   Rowe, B H ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERTOPARIN; DALTEPARIN; ENOXAPARIN; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN; TINZAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CANCER MORTALITY; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA EXTRACTION; EMBASE; HEART INFARCTION; HUMAN; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; PUBLICATION; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; UNSTABLE ANGINA PECTORIS;

EID: 44949127292     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003462.pub2     Document Type: Review

References (73)

1. Cohen 1990 {published data only} Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology 1990;66 (19):1287-92.
2. Cohen 1994 {published data only} Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al.Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation 1994;89(1):81-9.
3. Doucet 2000 {published data only} Doucet S, Malekianpour M, Theroux P, Bilodeau L, Cote G, Guise P, et al.Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restoneosis after coronary artery angioplasty. Circulation 2000;101(9):955-61.
4. FRISC 1996 {published data only} Swahn E, Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology 1997;80:25E-29E.
5. *Wallentin L. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347(9001):561-8.
6. Gurfinkel 1995 {published data only} Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, et al.Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology 1995;26(2):313-8.
7. Holdright 1994 {published data only} Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al.Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology 1994;24(1):39-45.
8. RISC 1990 {published data only} Wallentin L. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336(8719):830-7.
9. Theroux 1988 {published data only} Theroux P, H Ouimet, J McCans, Latour J.-G, Joly P, Levy G, et al.Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine 1988;319(17):1105-11.
10. Averkov 1993 Averkov OV, Zateischikov DA, Gratsiansky NA, Logutov YA, Yavelov IS, Yanus VM. Unstable angina pectoris: aspirin and heparin in a double-blind placebo-controlled study, their effects on the outcojjme of disease during hospitalization. Kardiologiya 1993;33(5):4-9.
11. Bodo 1995 Bodo I, Nemeth C, Littmann L, Holdright DR, Fox KM. Heparin and aspirin in unstable angina: insufficeitn sample size may lead to erroneous conclusions. Journal of the American College of Cardiology 1995;25(2):553-4.
12. Borja 2000a Borja J, Olivella P. Low molecular weigh heparin in the treatment of acute coronary syndromes without ST elevation: Unstable angina and non Q wave myocardial infaction [Hepariona de bajo peso molecuilar en el tratamiento de los sindromes coronarios agudos sin elevacion del degmento ST: angina inestable e infarto de miocardio sin onda Q]. Medicina Clinica 2000;115(15):583-6.
13. Borja 2000b Borja J, Campbell y Pere Olivella J, Magda H. Dalteparin in the acute phase of unstable angina and non-Q-wave infarction [Dalteparina en la fase cronica de la angina inestable e infarto sin onda Q]. Revista Espanola de Cardiologia 2000;53(8):1147-8.
14. Borja 2000c Borja J. Dalteparin for unstable angina and non-Q-wave myocardial infarction. Archives of Internal Medicine 2000;160(20):3169-70.
15. Charvat 1989 Charvat J, Kuruvilla T. Comparative study of heparin and antiplatelets in treatment of preinfarction angina. Cardiologia 1989;34:146-54.
16. Cohen 1993 Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, et al.Prospective comparison of unstable angina versus non-Q-wave myocardial infarction during antithrombotic therapy. Journal of the American College of Cardiology 1993;22(5):1338-43.
17. Collins 1996 Collins R, Baigent C, Peto R. Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA 1996;276:1873.
18. Correia 1995 Correia LC, Neubauer C, Azevedo A, Ribeiro F, Braga J, Passos LC, et al.The role of low molecular weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplast [O papel da heparina de baixo peso do miocardio e pos-angioplastia percutanea transluminal coronaria eletiva. molecular na angina instavel, infarto agudo]. Arquivos Brasileiros de Cardiologia 1995;65(6):475-8.
19. Emerg Med 1989 Preventing MI with heparin. Emergency Medicine 1989;June:74.
20. FAMI 2000 Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction. Indian Heart Journal 2000;52:533-9.
21. Ferguson 1999 Gerguson JJ, Zaqqa M. Platelet Glycoprotein IIb/IIa receptor antagonists current concepts and future directions. Drugs 1999;58:965-82.
22. FRISC II 1999 Ragmin F, Wallentin L, Swahn E, Kontny F, Husted S, Lagerqvist B, et al.Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354(9180):701-7.
23. Fujita 1988 Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 1988;77(5):1022-9.
24. GISSI-2 1990 Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, et al.GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336(8707):65-71.
25. Gorski 1993 Gorski J, Dmochowska-Wroblewska W. Heparin in myocardial infarction and unstable angina [Kliniki Chorob Zawodowych i Tropikalnych Instytutu Medycyny Morskiej i Tropikalnej, Gdyni]. Kardiologia Polska 1993;38(3):229-31.
26. Goy 1999 Goy JJ. Contemporary approach to management of unstable angina. Lancet 1999;354:694-5.
27. Gulba 1992 Gulba DC. Heparin therapy in coronary heart disease [Heparin-therapie bei koronarer herzkrankheit]. Deutsche Medizinische Wochenschrift 1992;117(1):35-6.
28. Hasselblad 1998 Hasselblad V. Meta-analysis of multitreatment studies. Medical Decision Making 1998;18(1):37-43.
29. Huber 1989 Huber K, Resch I, Rosc D, Probst P, Kaindl F, Binder BR. Heparin induced increase of T-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment. Thrombosis Research 1989;55:779-84.
30. Hurtado 1984 Hurtado L, Adabache M, Escarcega FL, Cardenas M. Acute myocardial infarction treated with anticoagulants [Evolucion hospitalaria del infarto agudo del miocardio tratado con y sin anticoagulantes]. Archivos del Instituto de Cardiologia de Mexico 1984;54(5):463-70.
31. Jaffrani 1993 Jaffrani NA, Ehrenpreis S, Laddu A, Somberg J. Therapeutic approach to unstable angina: nitroglycerin, heparin, and combined therapy. American Heart Journal 1993;126:1239-42.
32. Kaul 2000 Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin. Journal of the American College of Cardiology 2000;35:1699-712.
33. Kontny 2001 Kontny F. Improving outcomes in acute coronary syndromes - the FRISC II trial. Clinical Cardiology 2001;24(3 Suppl):I3-7.
34. Mattioli 1999 Mattioli AV, Tarabini Castellani E, Goedecke L, Sormani L, Sternieri S, Mattioli G. Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study. Clinical Cardiology 1999;22(3): 213-7.
35. Milonig-Ganner 1989 Millonig-Gannjer. [Koronarer bypass: erfolg hangt oft von psyche ab]. Arch Medici Nr 1989;8:433-4.
36. Moise 1994 Moise A, Roos M. Aspirin versus heparin in the acute phase of unstable angina. Circulation 1994;90:1107.
37. Montgomery 1995 Montgomery HE, Chester MR. Heparin in unstable angina. Lancet 1995;346:248.
38. Nardelli 1991 Nardelli A, Bottero G, De Francesco A. Study on the efficacy of heparin and aspirin in unstable angina and acute heart infarction [Cosa hanno insegnato i grandi trials sull'eparina e sull'aspirina nell'angina instablile e nell'infarto miocardico acuto]. Clinica e Terapia Cardiovascolare 1991;10(3):171-7.
39. Ocampo 1998 Ocampo S, Solorio S, Rangel A, Leon FJ, Lepe L, Ayala F, et al.Low molecular weight heparin in unstable angina pectoris [La heparina de bajo peso molecular en la angina de pecho inestable]. Archivos del Instituto de Cardiologia de Mexico 1999;69:222-227.
40. Oler 1996 Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarctionand death in patients with unstable angina. JAMA 1996;276:811-5.
41. PURSUIT 2001 Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104(23):2772-7.
42. Raschke 1993 Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Annals of Internal Medicine 1993;119:874-81.
43. Rubio-Terres 2001 Rubio-Terres C, Pajuelo F, Margalet I. Low-molecular-weight heparins in unstable angina and non-Q-wave myocardial infarction [Heparinas de bajo peso molecular en la angina inestable y el infarto de miocardio sin onda Q]. Medicina Clinica 2001;116(16):638-9.
44. Sayen 1982 Sayen JJ, Singer RB, Peirce G, Horwitz O. Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event - first year and long-term cmparativemortality. Transactions of the American Clinical & Climatological Association 1982;94:141-53.
45. Serneri 1988 Serneri GGN, Abbate R, Prisco D, Carnovali M, Fazi A, Casolo GC, et al.Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin: a controlled cross-over randomized study. American Heart Journal 1988;115:60-6.
46. Serneri 1990 Serneri GGN, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, et al.Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in regractory unstalbe angina. Lancet 1990;335:615-8.
47. Serneri 1995 Serneri GGN, Modesti PA, Gensini GF, et al.Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995;345:1201-4.
48. Spodick 1989 Spodick DH. Aspirin, heparin, or both to treat unstable angina. New England Journal of Medicine 1989;320:1014.
49. TETAMI 2000 Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, et al.The TETAMI Trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acutemyocardial infarction for patients not thrombolyzed: methods and design. Journal of Thrombosis & Thrombolysis 2000;10:241-6.
50. Theroux 1993 Theroux P, waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to preventmyocardial infarction during the acute phase of unstable angina. Circulation 1993;88(5 Pt 1):2045-8.
51. Thieuleux 1985 Thieuleux FA, Vilarem D, Lablanche JM, Asseman PA, Thery C, Bertrand ME. Management of unstable angina pectoris with maximal medical treatment (combination of intravenous nitrates, beta-blockers, calcium antagonists and heparin). Bibliotheca Cardiologica 1985;39:88-96.
52. Umans 1997 Umans VA, Kloeg PH, Bronzwaer J. The CAPTURE trial. Lancet 1997;350:445.
53. Violaris 1991 Violaris AG, Campbell S. Low-dose aspirin and heparin in ujnstable coronary artery disease. Lancet 1991;337:489- 90.
54. Wallentin 1997 Wallentin L, Husted S, Kontny F. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II study). American Journal of Cardiology 1997;80:61E-63E.
55. Wallis 1991 Wallis DE, Boden WE, Califf R, Crawford MH, Hakki AH, Iskandrian AS, et al.Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. American Heart Journal 1991;122:949-54.
56. Zwerner 1987 Zwerner P, Gore J, Corrao J, et al.Heparin in the treatment of unstable angina: a randomized prospective trial. Circulation 1987;76(Suppl IV):IV-180.
57. ACLS 2000 ACLS. Part 7: the era of reperfusion. Section 1: acute coronary syndromes (acute myocardial infarction). Circulation 2000;102(Suppl I):172-303.
58. Braunwald 2000 Braunwald E. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation of myocardial infarction. Executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2000;102:1193-209.
59. Cairns 1989 Cairns JA, J Singer, M Gent, et al.One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or chest pain in Hamilton, Ontario, a city of 375,000 people. Canadian Journal of Cardiology 1989;319:239-46.
60. Clarke 2001 Clarke M, AD Oxman, editors. Assessment of study quality. Cochrane Reviewers Handbook 4.1.3 [updated june 2001]; Section 6. Cochrane Reviewers Handbook. Oxford: Update Software, 2001.
61. Cohen 1998 Cohen M. Approaches to the treatment of unstable angina and non-Q wave myocardial infarction. Canadian Journal of Cardiology 1998;14(Suppl E):11E-14E.
62. Egger 1997 Egger M, Davey Smith G, Schnieder M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
63. Eikelboom 2000 Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42.
64. Fuster 1995 Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. American Journal of Cardiology 1995;76:24C-33C.
65. Higgins 2003 Higgins JP, Thompson SG, Deek JJ, Altman DG. Bias in meta-analysis detected by a simple, graphical test. BMJ 2003;327:557-60.
66. Hirsh 1998 Hirsh j, Warkentin TE, Raschke R, et al.Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S.
67. Jadad 1996 Jadad AR, RA Moore, D Carroll, C Jenkinson, DJ Reynolds, DJ Gavaghan, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
68. Landis 1977 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
69. Lewis 1983 Lewis HD, Davis JW, Archibald DG, et al.Proctective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results fo a Veterans Administration Cooperative Study. New England Journal of Medicine 1983;309:396-403.
70. Libby 2002 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
71. Magee 2003 Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 1.Art.No.: CD002132. DOI:10.1002/14651858.CD002132.
72. Weitz 1997 Weitz JE. Low molecular wieght heparins. New England Journal of Medicine 1997;337:688-98.
73. Wong 2003 WongGC,Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. Journal of the American Medical Association 2003;289:331-42.